TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03032692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWORD
Description: Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWORD
Description: Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with biofeedback

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise without biofeedback
Study: NCT03013647

Intervention type: DRUG
Group type: OTHER
Intervention: Methyl Aminolevulinate
Description: Patients will be treated with Daylight Photodynamic therapy, following these steps:~1. mild curettage of the AK lesions~2. application of a chemical sunscreen SPF 30~3. application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)~4. exposition to daylight, for 120 minutes~5. cleaning of the face
Study: NCT01615445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
Study: NCT03394794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation
Description: The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation
Description: The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation
Description: The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
Study: NCT01444469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zithromax
Description: 250mg \* 2 capsules once daily for three days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose powder
Study: NCT03540342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One stop strategy group
Description: Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
Study: NCT02153697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q-switched SINON Ruby Laser
Description: Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pigmanorm Cream
Description: Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
Study: NCT04198610

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal therapy
Description: Procedure/Surgery: non surgical periodontal therapy and root planing (SRP) was performed in two to four appointments lasting approximately 60 minutes each under local anaesthesia (2% lignocaine hydrochloride with 1:2,00,000 adrenaline) using area specific Gracey periodontal curettes and an ultrasonic device. The treatment was concluded in 3 months. Within the duration of the study, all subjects received supportive therapy, which included professional plaque control and reinstruction of oral hygiene.
Study: NCT01071720

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-501 1mg
Description: This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.

Intervention type: DRUG
Group type: OTHER
Intervention: CKD-501 1mg
Description: This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
Study: NCT00730925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: tablet BIBW high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992 + paclitaxel
Description: tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
Study: NCT01954017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STP206
Description: Live Biotherapeutic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Sterile Water
Study: NCT04315311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CREON
Description: Capsule: Oral
Study: NCT03453333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D laparoscope
Description: For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D laparoscope
Description: For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
Study: NCT02292732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 0.5 mg
Description: Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter \[mm\]) to be taken orally and once daily
Study: NCT00771680

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency at the discretion of the physician following clinical practice
Study: NCT02292732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg
Description: Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORTHO-NOVUM® tablet 1/35
Description: Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each green tablet will contain only inert ingredients: D\&C yellow No. 10 Aluminum Lake, FD\&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
Study: NCT00771680

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency at the discretion of the physician following clinical practice

Intervention type: DRUG
Intervention: insulin aspart
Description: Start dose and frequency at the discretion of the physician following clinical practice
Study: NCT01501318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback report
Description: Participants receive the personalized feedback report but no additional education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized feedback report plus education
Description: Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
Study: NCT03917290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants. Due to in-person restrictions that have resulted from COVID-19, participants may also complete the intervention via remote (virtual) training sessions.
Study: NCT04133844

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
Study: NCT03474159

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level

Intervention type: DEVICE
Group type: OTHER
Intervention: Transthoracic echocardiography
Description: Aortic distensibility measured in TTE of the same segments in TM and in B mode

Intervention type: DEVICE
Group type: OTHER
Intervention: Echography UltraFast
Description: Carotid pulse rate measured on carotid arteries by UF
Study: NCT01235039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject®25
Description: Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject®7
Description: One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
Study: NCT02093078

Intervention type: BEHAVIORAL
Intervention: CARD
Description: Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay.
Study: NCT03372395

Intervention type: OTHER
Group type: OTHER
Intervention: Lactobacillus rhamnosus BMX 54
Description: Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus BMX 54
Description: Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
Study: NCT00677170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
Study: NCT01262729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutical hypothermia
Description: Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutical hypothermia
Description: Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon Inhalation
Description: Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
Study: NCT02480855

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire and feedback
Study: NCT00480363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintenance with lower doses of lenalidomide and dexamethasone
Description: After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
Study: NCT04359186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Interruption Arm
Description: Individuals with HIV on suppressive ART will interrupt their ART.
Study: NCT04085263

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The patients in this group will receive sham rhomboid intercostal and subserratus plane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal and subserratus plane block group
Description: The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
Study: NCT00945971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
Study: NCT04141293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar recruitment
Description: Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
Study: NCT00534521

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Tibial Nerve Device
Description: The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
Study: NCT01681446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon-alpha (IFN-alpha)
Description: interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
Study: NCT01621334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Two personal feedback sessions with counselor using motivational interviewing strategies.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational information
Description: Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
Study: NCT02716714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ingenol mebutate gel 0.015%
Description: -Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ingenol mebutate gel 0.05%
Description: -Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
Study: NCT05494710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleomycin electrosclerotherapy treatment
Description: The combination of Bleomycin and electroporation of the treated area which is called electrochemotherapy (ECT).
Study: NCT04666948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vancomycin model-informed precision dosing
Description: A CE labelled dosing calculator is used for a priori and a posteriori calculation of vancomycin dose using a target AUC between 400-600 mg\*h/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin treatment
Study: NCT01904695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbs
Description: Herbs 180ml by mouth every 12 hours for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive drugs
Description: Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Description: Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
Study: NCT04181294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family meetings using time limited trials as default ICU communication and care planning approach
Description: Providers will be trained using didactics, focus groups, and simulations using actors as family members. A TLT protocol and checklist will be used to facilitate family meetings. A coordinator will schedule family meetings. Routine feedback sessions will be held with the local champions.
Study: NCT03177993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 drug dose - IDA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 drug dose - IDA with second dose of ivermectin
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to ivermectin, diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 drug dose - DA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~* severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~* allergy to diethylcarbamazine or albendazole;~* pregnant;~* breastfeeding within 7 days of delivery;~* less than 2 years old; OR~* less than 15 kg~Exclusion criteria for permethrin:~* allergy to permethrin~* crusted scabies
Study: NCT01220908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Volume Reduction Coil (LVRC)
Description: Implantation of Lung Volume Reduction Coil(s) (LVRC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coils
Description: Lung Volume Reduction Coil(s)
Study: NCT00534521

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
Study: NCT03056716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silastic vs conventional drain in thoracic surgery
Description: Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silastic vs conventional drain in thoracic surgery
Description: Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
Study: NCT04506346

Intervention type: DIAGNOSTIC_TEST
Intervention: difficult tracheal intubation
Description: Grade Ⅲ or Ⅳ according to Cormach-Lehane Grading of laryngoscopic view
Study: NCT01602315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 as film-coated (FC) whole tablets
Description: Oral alpha-specific PI3K inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719 as film-coated (FC) whole tablets
Description: Oral alpha-specific PI3K inhibitor
Study: NCT01059942

Intervention type: OTHER
Intervention: mock handoff exposure
Description: Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.

Intervention type: OTHER
Intervention: Introduction of CEX tool in Actual Hand-offs
Description: We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
Study: NCT02280915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Savoury food product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Savoury food product